UBS Upgrades Medpace Holdings to Neutral, Raises Price Target to $673
UBS analyst Kevin Caliendo upgrades Medpace Holdings (NASDAQ:MEDP) from Sell to Neutral and raises the price target from $405 to $673.
Share
Why It Matters
A big bank analyst changed their mind about Medpace and now likes it better. This suggests the company might be doing better things than they thought before.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.